# ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

> **NCT07173751** · PHASE3 · RECRUITING · sponsor: **BioNTech SE** · enrollment: 558 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Pumitamig
- **DRUG:** Nab-paclitaxel/Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Eribulin
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT07173751
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-30
- **Primary completion:** 2029-12
- **Final completion:** 2030-09
- **Target enrollment:** 558 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07173751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07173751, "ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT07173751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*